(Q38536391)

English

First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study

scientific article published on 23 June 2015

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study (English)

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

0 references

1 reference

based on heuristic

inferred from title

21

object named as

F Xia

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

author name string

Y-L Wu

1

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

C Zhou

2

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

C-K Liam

3

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

G Wu

4

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

X Liu

5

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

Z Zhong

6

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

S Lu

7

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

Y Cheng

8

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

B Han

9

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

L Chen

10

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

C Huang

11

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

S Qin

12

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

Y Zhu

13

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

H Pan

14

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

H Liang

15

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

E Li

16

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

G Jiang

17

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

S H How

18

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

M C L Fernando

19

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

Y Zhang

20

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

Y Zuo

22

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

publication date

23 June 2015

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

Annals of Oncology

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

26

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

9

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

1883-1889

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

Cancer statistics, 2013

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV270

21 January 2018

EGFR through STAT3 modulates ΔN63α expression to sustain tumor-initiating cell proliferation in squamous cell carcinomas.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV270

21 January 2018

Screening for epidermal growth factor receptor mutations in lung cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV270

21 January 2018

Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV270

21 January 2018

Epidermal growth factor receptor mutations and their correlation with gefitinib therapy in patients with non-small cell lung cancer: a meta-analysis based on updated individual patient data from six medical centers in mainland China

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV270

21 January 2018

Efficacy of EGFR tyrosine kinase inhibitors in non-small-cell lung cancer patients with/without EGFR-mutation: evidence based on recent phase III randomized trials

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV270

21 January 2018

Erlotinib in previously treated non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV270

21 January 2018

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV270

21 January 2018

The impact of EGFR T790M mutations and BIM mRNA expression on outcome in patients with EGFR-mutant NSCLC treated with erlotinib or chemotherapy in the randomized phase III EURTAC trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV270

21 January 2018

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV270

21 January 2018

A prospective, phase II, open-label study (JO22903) of first-line erlotinib in Japanese patients with epidermal growth factor receptor (EGFR) mutation-positive advanced non-small-cell lung cancer (NSCLC).

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV270

21 January 2018

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV270

21 January 2018

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV270

21 January 2018

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV270

21 January 2018

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV270

21 January 2018

Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV270

21 January 2018

Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV270

21 January 2018

Better survival with EGFR exon 19 than exon 21 mutations in gefitinib-treated non-small cell lung cancer patients is due to differential inhibition of downstream signals

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV270

21 January 2018

Identifiers

10.1093/ANNONC/MDV270

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38536391&oldid=2196088871"